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Summary.-A TLX-5 mouse lymphoma which was resistant to 1-,B-D-arabino-
furanosyl cytosine (AraC) was used in vivo to studythepossibility of using liposomes
as drug-delivery vehicles in order to overcome drug resistance.
The effects of free drugs (AraC, AraCTP and methotrexate) and the liposomally
associated drugs on the survival time of tumour-bearing mice were determined.
As a more sensitive measure of cell survival, 125IUdR was incorporated into the
DNA of the ascites TLX-5 cells before i.p. injection. Cell survival and the cytotoxic
effects of the drugs on the tumour cells were determined by using a double-headed
gamma counter to measure the retention of the 125I label.
Both AraC and AraCTP, either as the free drugs or liposomally associated, had no
effects on the tumour. Due to the lack of response of tumour cells to these drugs,
further studies were initiated with free and liposomally associated methotrexate
(MTX), a drug to which the cells were known to be sensitive. It was found that the
liposomally associated MTX, at a 5-10-fold lower dose than the free drug, was (a)
more effective in prolonging the survival of tumour-bearing mice and (b) as effective
as the free drug in killing tumour cells (as measured by the 1251 retention).
In vivo MTX was more effective in the liposomally associated form, whereas
liposomally entrapped AraC and AraCTP were ineffective. It is proposed that in
vivo liposomally associated drugs may be acting not by actively localizing in the
tumour cells, but by the liposomes providing a slow-release drug depot, improving
the pharmacokinetic properties of MTX.
A NUMBER OF AUTHORS have previously
reported the successful application of
liposomally trapped anti-tumour drugs
in the treatment of several animal tu-
mours in vivo (Gregoriadis & Neerunjun,
1975; Kimelberg & Achison, 1978; Koba-
ashi et al., 1977; Kosloski et al., 1978;
Mayhew et al., 1976, 1978a, b). How-
ever, there are doubts as to the exact
mechanism(s) by which liposomally trap-
ped drugs exert their therapeutic effects.
They may act in a number of ways:
(a) by accumulating in tumour tissue
(Neerunjun et al., 1977), (b) by acting as a
drug storage depot, slowly releasing drug
over a longer period (Juliano & Stamp,
1978), or (c) by reducing toxicity to the
normal tissues of the animal (Rahman
et al., 1978). Studies in drug-resistant
tumours have proved useful in analysing
some of these problems, as well as looking
at the possibility of using liposomes to
overcome drug resistance (Kaye et al.,
1980; Papahadjopoulos & Post, 1976;
Richardson et al., 1982).
Using the same TLX-5 AraC-resistant
tumour cell line as used in the in vitro
studies outlined in the accompanying
paper (Richardson et al., 1982), we set
out to analyse the possibilities of using
the AraCTP trapped in liposomes to
overcome drug resistance in vivo.
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METHODS
Preparation of liposomes.-Liposomes were
prepared from compositions of egg phospha-
tidyl choline (PC), cholesterol (C), phospha-
tidic acid (PA) and stearylamine (SA). Most
experiments were performed with liposomes
composed of a 7:2: 1 molar ratio ofPC:C:PA.
One hundred mg of lipids in chloroform
were rotary-evaporated to dryness under
vacuum at 36°C. To the dry lipid film was
added either physiological saline (1 ml) or
the drugs AraC, AraCTP or MTX in an
identical volume of saline. The lipid was
allowed to swell in the aqueous solution,
and was agitated to remove all traces of lipid
from the sides of the flask. The flask was
then surrounded by an ice bath and, using
an exponential 2mm diameter titanium
probe, was sonicated for 10 bursts of 30 sec
with 30 sec cooling between, using a 120W
sonicator setting of 6-8 ,um peak-to-peak.
This treatment produced liposomes with
diameters of the order of 50-100 nm. Lipo-
somes thus prepared were then left for 30
min before G50 filtration to separate from
free drugs.
Liposomes and liposomes containing drugs
were sterilized by passage through sterile
0 45 ,m millipore filters into sterile ampoules.
A small proportion of the drug-containing
samples were taken for spectrophotometric
(MTX) or radioactive (AraC and AraCTP)
determination of the drug content. This was
diluted as required with empty liposomes to
the desired concentrations for treatment.
Liposomes were administered i.p. in 0 5 ml
daily for the first 5 days.
Animals and tumour passage.-Tumours
were passaged in CBA mice at weekly
intervals. Ascites fluid containing the cells
was collected, diluted 1:10 with Hanks'
buffered saline (HBS) and 0-1 ml (_ 106
cells) injected i.p. into fresh mice. All experi-
ments were performed with groups of CBA
mice weighing 25-30 g.
1251-tabelling of tumour cells.-The DNA
of the tumour cells was labelled with 125IdU
by a method similar to that of Porteous &
Munro (1972). Five days after i.p. injection
of 106 tumour cells, a group of mice was
injected with 1-0 jtCi each of 125IdU in
0-2 ml of saline at 3 h intervals until a total
dose of4 0 ,uCi had been given. Two days later
ascitic fluid was collected and the cells were
centrifuged, washed x 3 in HBS and 125IdU
37
incorporation determined by measurement in
a gamma counter.
Measurement of cell survival.-After i.p.
injection of 107 125I-labelled tumour cells,
mice were restrained in small ventilated
plastic boxes, between the double-headed
detectors of a gamma counter to obtain a
baseline of the activity in each mouse.
Survival of the tumour cells was monitored
by following the retention of the 1251 label,
and comparing control and drug-treated
groups. The survival time of individual mice
was recorded daily for control and treated
groups
Blood levels of [3H]-MTX.-[3H]-MTX,
either free or entrapped, was injected i.p.
into tumour-bearing mice 6 days after
inoculation of 106 TLX-5 tumour cells. At
various times, pairs of mice were killed and
blood levels of the label determined.
RESULTS
Table I shows the effects oftwo liposome
lipid compositions on both the survival
time of tumour-bearing mice and the
survival of the tumour cells as measured
by 1251 retention. This table shows lack
of toxicity for the negatively charged
PC:C:PA) liposomes, even at a dose of
4 g/kg daily for 5 days. The positively
charged liposomes (PC:C:SA) at 0 4
g/kg daily do show tumour-cell cyto-
toxicity, represented as 33% reduction
in the level of 1251 label retained. How-
ever, there was also a 32% reduction in
the time that the tumour-bearing mice
survive, indicating that these liposomes
were toxic to the mouse. It was for this
reason that PC:C:SA was not used for
further study. The drugs AraC and
AraCTP, either free or entrapped in
liposomes composed of PC:C:PA, had
no effect on tumour-cell cytotoxicity, and
only with the highest dose of free AraC
(20 mg/kg) was there any sign of toxicity
as a reduction in survival time. Even at
this high dose, there was no observable
effect on the tumour cells (no change in
1251 retention as compared to the control
group), indicating the very high resistance
of the tumour to AraC.
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TABLE I.-Effect of liposomal lipid, free and liposomally associated AraC and AraCTP
on tumour-cell cytotoxicity in vivo and survival time of tumour-bearing mice
Treatment
Saline
Liposomes (PC:C:PA)
Liposomes (PC:C:SA)
AraC (free)
AraC (in liposomes PC:C:PA)
AraCTP (free)
AraCTP (in liposomes PC:C:PA)
Dose (mg/kg daily
over 5 days)
Lipid Drug
o o
4000 0
400 0
0 20-0
800 6-0
0 9*3
800 6-4
Lipid abbreviations: PC=Phosphatidylcholine (egg lecithin), C = cholesterol, PA = Phosphatidic acid,
SA =Stearylamine.
* Reduced survival time due to toxicity to mice, as well as to tumour cells.
t Highdose AraC showing toxicity to mice and tumour-cell resistance.
I Average survival time of control mice: 7 1 days.
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FIG. 1.-Effect of various dose levels of free
MTX on the survival of 125I-labelled TLX-
5 tumour cells as measured by 125I reten-
tion. =Injection of drugs (i.p. daily for
5 days); 0 =controls (given saline);
*0-1 mg/kg MTX; A = 1*8 mg/kg MTX;
* = 18-0 mg/kg MTX; t=all mice dead.
Fig. 1 shows the effect of various doses
of free MTX on the survival in vivo of
the TLX-5 tumour cells, as measured by
the retention of the 1251 label. A control
group and 3 drug-treated groups of 5
mice were used. Doses of MTX were
chosen to fall either side of the most
effective dose (1P8 mg/kg) when given
daily for 5 days.
The two highest doses of MTX (IP8
and 18 mg/kg daily) show a similar rate
of cell kill, as shown by the 1251-retention
curves. With the highest dose (18 mg/kg
daily) all mice died sooner than control
groups, indicating high toxicity. The
most effective dose of MTX was 1P8
mg/kg daily, as measured by the 1251
retention. Treated groups given this dose
of drug had, by Day 5, only 6% retention
oflabel versus 55% in control groups.
The lowest dose of MTX (0-1 mg/kg
daily) was less effective at killing tumour
cells, and had no measurable prolongation
of mouse survival.
Fig. 2 shows the effect of various dose
levels of liposomally trapped MTX on
the survival in vivo of the TLX-5 tumour
cells, as measured by the retention of
1251 label. A control group and 3 treated
groups of 5 mice were used. Doses of
entrapped drug chosen to give values
either side of the most effective dose
(0.1 mg/kg daily) were less effective, but
still significantly below the control group.
Fig. 3 shows the dose response and
changes in survival times of tumour-
bearing mice treated with free and
liposomally trapped MTX. The optimal
concentration of free MTX was 1 mg/kg
i.p. daily for 5 days, giving a 35% in-
crease in survival time over controls. The
% Cell death
on Day 5
0
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0
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FIG. 2.5Effect of various (ose levels of
liposomally trapped MTX on the survival
of 125-eabelled TLX-5 tumour cells as
measure(d by 1251 retention. f=Injection
of (drugs (i.p. daily for 5 days). Liposome
composition PC: C: PA (7: 2: 1 molar ratio).
Dose of lipidy 4050 mg/kg/day; f =
controls (given saline); * = U0l0 mg/kg lipo-
somal MITX; A= 01 mg/kgliposomalMTX
m 1. 0 mg/kg liposomal MTX; =all miece
dleadl.
optimal concentration for liposomally
trapped MTX was -02 mg/kg daily for
5 days. At this level of drug there was a
600 increase in survival time over
controls.
The therapeutic range of doses which
prolonged survival were, for the free
drug, 0-7-2 mg/kg (daily for 5 days) and,
for the liposomally trapped drug, 0-07-
0-5 mg/kg (daily for 5 days).
The liposomal form of MTX was thus
more effective at prolonging the survival of
the mice, and this at 5-10 times lower
doses of drug than the most active dose
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FIG. 3.-Dose-response curve for free and
liposomally trapped MTX, showing survival
of mice bearing the TLX-5 lymphoma.
A =Free MTX; * =liposomally trapped
MTX. (Lipid=PC:C:PA, 7:2:1 Molar
ratio). Drugs were given i.p. daily'for 5
days.
of free drug. The liposomally trapped
MTX also appeared to be therapeutically
more active over a slightly wider range of
concentrations.
Table II compares the effects of liposo-
mally trapped MTX, free MTX and
empty liposomes mixed with free MTX
on the survival times of tumour-bearing
mice, for two doses of MTX.
There appeared to be no difference in
results between the free form of the drug
and the free drug mixed with empty
liposomes at the concentration tested.
At the higher dose of MTX the free drug
was more active in prolonging survival,
whereas at the lower dose the liposomally
trapped drug was most effective.
Fig. 4 shows the plasma levels of
[3H]-MTX after i.p. administration of
free or liposomally trapped [3H]-MTX.
The free drug was cleared most rapidly
from the plasma. The liposomal form of
the drug was cleared less rapidly and
remained about 10 x the level of the
free drug over the 6 h period of measure-
ment.
DISCUSSION
In the accompanying paper (Richardson
et al., 1982) we showed that in vitro
liposomally trapped AraCTP was able to
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TABLE II.-Survival times of TLX-5 tumour-bearing mice (injected i.p. with 106 tumour
cells) after treatment with variousforms of MTX
Treatment
Saline
MTX
MTX+empty liposomes (40 mg)
Liposomal MTX (40 mg lipid)
Saline
MTX+empty liposomes (40 mg)
Liposomal MTX (40 mg lipid)*
Drug dose
(mg/kg daily
for 5 days)
1.0
1.0
1.0
0*1
0-1
0-1
Mean survival time
(days +s.d.)
6-8+0-4 (6)t
11-0+0-7 (5)
11-6+0-6 (5)
6-2+0-5 (5)
7 *4+ 10 (7)
8-2+1-6 (5)
12*3+1-5 (6)
* Lipid composition, 7: 2: 1 molar ratio PC:C:PA.
t No. animals in parentheses.
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FIG. 4.-Blood levels of [3H]-MTX following
injection of free drug or liposomally
trapped drug. Two groups of CBA mice
5 days after i.p. injection of 106 TLX-5
AraC-resistant tumour cells were injected
i.p. with either 1 ,uCi of [3H]-MTX in 20
Hg free MTX (-) or 1 ,uCi [3H]-MTX in 20
,ug liposomally trapped MTX (0) ( 40
mg of lipid composed of 7:2:1 molar ratio
PC:C:PA, prepared as in Materials and
Methods).
overcome AraC resistance in the drug-
resistant TLX-5 lymphoma. This tumour
was also selected for our in vivo studies
for several reasons. These were: firstly,
that it grew well as an ascites tumour,
and i.p. injection of liposomally trapped
drug would produce direct contact
between liposomes and tumour cells;
secondly, there would be no blood-
vessel permeability barrier to overcome,
as there would be with a solid tumour
(Underwood & Carr, 1972); thirdly, the
slow drainage of the ascites fluid from the
peritoneal cavity would possibly pro-
long the contact between tumour cells
and liposomes, allowing greater inter-
action; fourthly, we could test whether
liposomes were taken up by tumour cells
in vivo and thus able to overcome drug
resistance. If this had occurred, we
would have expected to see tumour-cell
cytotoxicity only if liposomes containing
AraCTP were to fuse with or be endo-
cytosed by the tumour cells. Any leakage
of AraCTP from liposomes would not
interfere, as free AraCTP would not be
readily taken up by cells. Even the leak-
age of AraCTP and conversion to AraC
would not interfere, as the cells are
highly resistant to AraC (Richardson
et al., 1982).
The lack of effectiveness of the lipo-
somally trapped AraCTP on the TLX-5
AraC-resistant cell line indicated that the
liposomes may not help AraCTP to
enter the cells in vivo. Considering the
results of the in vitro studies (Richardson
et al., 1982), it appears that the liposomes
may not have been endocytosed or may
not have fused with the tumour cells
under the in vivo conditions, and if
either of these did occur the extent was
insufficient to produce significant effects.
We have observed many endocytic vesi-
cles in the TLX-5 cells, which suggests
that they are actively endocytic (unpub-
lished data).
There is also a possibility that the
liposomes in vivo were unstable in the
Experiment
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ascitic fluid, causing rapid leakage of the
AraCTP from the liposomes, as has been
reported by other workers with liposomes
in serum (Sherphof et al., 1978).
Both liposomally trapped and free
MTX were effective against the tumour,
which indicates a significant difference
between this drug and AraC. The tumour
cells had no intrinsic resistance to MTX.
Therefore if the drug leaked from the
liposomes and then entered the tumour
cells there would be an observable cyto-
toxicity. We cannot, therefore, test
whether the effects we observed were due
to tumour localization of liposomes con-
taining MTX or to the leakage of the
drug from the liposomes followed by its
entry into the cells. Liposomally trapped
MTX was more effective against the
tumour than was the free drug. It seems
very likely that this is due to liposomes
prolonging the exposure of the tumour
cells to MTX, by acting as a slow-release
storage depot. This is compatible with
the observed blood levels of MTX after
administration of free and entrapped
MTX (Fig. 4).
Other workers have shown that both
AraC and MTX are more effective against
tumours when given as a slow infusion
(Tattersall, 1977). It is believed that this
is due to changes in the pharmacokinetics
of the drugs leading to higher and pro-
longed levels of the drugs in the bood
and tissues. It has also been shown, using
AraC and MTX in water-oil-water emul-
sions, that this presentation served as a
slow-release storage depot and prolonged
the half-life of the drugs (Benoy et al.,
1974) and also increased their effective-
ness against tumours at lower dose
levels
As our studies have shown no activity
with entrapped AraCTP but have with
MTX, we propose that this slow release
was the mechanism by which liposomes
were acting in our studies. The blood
levels of MTX when the drug was admin-
istered in the free and entrapped form
suggest this may be the case. Blood
levels with the entrapped drug were
5-10 x the levels observed for identical
doses of the free drug. This value corres-
ponds to a 5-10-fold lower dose of the
liposomal form of the drug to give a
similar effect to that with the free drug.
Obviously more biochemical work is
required to elucidate fully what is happen-
ing when AraCTP is administered in
liposomes, but it appears that the use of
liposomes will not simply overcome drug
resistance to AraC.
It is important, however, that liposo-
mal entrapment did have some effects
with methotrexate, and may therefore
have some therapeutic advantages in
prolonging localized release of anticancer
drugs. This may be of great value in the
treatment of certain tumours in the lym-
phatics, a tissue in which liposomes
have been found to localize greatly
after interstitial injection (Richardson
et al., 1978).
WN'e would like to thaink the Cancei Research
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